Harrow Inc reports results for the quarter ended December 31 - Earnings Summary
27/03/2025 22:28
Harrow Inc HROW.OQ reported quarterly adjusted earnings of 24 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of five analysts for the quarter was for earnings of 7 cents per share. Wall Street expected results to range from -1 cents to 17 cents per share. Revenue rose 83.8% to $66.83 million from a year ago; analysts expected $61.79 million. Harrow Inc's reported EPS for the quarter was 24 cents. The company reported quarterly net income of $6.78 million. Harrow Inc shares had fallen by 17.6% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 231.7% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Harrow Inc is $57.00 This summary was machine generated from LSEG data March 27 at 10:27 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | 0.07 | 0.24 | Beat |
| Sep. 30 2024 | -0.05 | -0.12 | Missed |
| Jun. 30 2024 | -0.20 | -0.18 | Beat |
| Mar. 31 2024 | -0.20 | -0.38 | Missed |
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates